编号：2024-006 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 投 资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 | --- | --- | |------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 现场参观 □ 其他（线上会议） | | 参与人员 | 珠海上市公司协会、华泰证券、广州私募基金协会、汇聚投资、玄甲基金、 宸 泽基金、太朴持信 ...

| 证券代码：300529 | 证券简称：健帆生物 公告编号：2024-083 | | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | 健帆生物科技集团股份有限公司 第五届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十三 次会议于 2024 年 11 月 21 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》 的有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。 公司董事长董凡先生召集和主持了本次会议，公司部分监事和高级管理人员列席 了会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于聘任副总经理的议案》 根据《公司法》《公司章程》及其他有关规定，结合公司发展需求，由公司 总经理提名，经董事会提名委员会资格审查 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-084 截至本公告日，李峰先生直接持有公司股份 75.58 万股，占公司总股本的 0.09%； 持有公司奋斗者一号员工持股计划 300 万元份额，占该持股计划总份额的 2.2%，折 合通过员工持股计划间接持股数量 12.25 万股，占公司总股本的 0.02%。其与持有 公司 5%以上股份的股东、公司其他董事、监事、高级管理人员不存在关联关系， 未受过中国证监会及其他有关部门的处罚和证券交易所惩戒，不存在《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》第 3.2.3 条规定 的情形。经查询，李峰先生不属于最高人民法院网站列示的"失信被执行人"。 李峰 先生具备履行高级管理人员职责所必需的专业知识和工作经验，其任职资格、聘任 程序均符合《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等法律、法规、规范性文件及《公司章程》的相关规定。 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于聘任副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整 ...

Investment Rating - The report maintains a "Buy-A" investment rating with a target price of 40.29 CNY for the next six months [4][6]. Core Insights - The company has demonstrated strong growth in the first three quarters of 2024, achieving a revenue of 2.196 billion CNY, a year-on-year increase of 47.76%, and a net profit of 792 million CNY, up 86.86% [1]. - In Q3 2024, the company reported a revenue of 700 million CNY, reflecting a 47.74% year-on-year growth, and a net profit of 239 million CNY, which is a 63.62% increase compared to the same period last year [1]. - The gross margin for the first three quarters of 2024 was 81.31%, an increase of 0.65 percentage points year-on-year, while the net margin was 35.93%, up 7.64 percentage points year-on-year [2]. - The company has maintained a healthy inventory level, which is expected to support future revenue and profit growth [3]. Financial Performance Summary - Revenue growth rates for 2024 to 2026 are projected at 50.2%, 26.3%, and 23.9% respectively, while net profit growth rates are expected to be 110.6%, 25.9%, and 22.6% [4][9]. - The company’s gross profit margin is projected to be 80.3% in 2024, with a net profit margin of 31.8% [9]. - The earnings per share (EPS) is expected to increase from 0.55 CNY in 2023 to 1.15 CNY in 2024, and further to 1.78 CNY by 2026 [9].

证券研究报告 健帆生物 (300529 CH) 3Q24 公司业绩延续快速增长势头 华泰研究 季报点评 2024 年 10 月 19 日│中国内地 医疗器械 健帆生物发布 24 年三季报：1-3Q24 实现收入 21.96 亿元（yoy+47.8%）、 归母净利润 7.92 亿元（yoy+86.9%），其中 3Q24 实现收入 7.00 亿元 （yoy+47.7%）、归母净利润 2.39 亿元（yoy+63.6%）。公司血液灌流器、 吸附器等核心产品销售放量喜人，驱动整体业绩快速增长。考虑血液灌流疗 法渗透率持续提升、公司产品学术推广进一步强化，叠加前期内部营销改革 成效陆续显现，我们看好公司 24 全年业绩保持快速增长势头。维持买入。 看好公司核心产品 24 年收入保持快速增长 我们推测公司血液灌流器等核心产品 1-3Q24 整体收入同比实现快速增长。 公司核心产品院内认可度高、循证证据丰富且新品推广进展顺利，包括：1） 院内认可高：截至 1H24，公司肾科、肝科产品医院覆盖量分别超 6000/2000 家；2）循证证据多：截至 1H24，公司肾科 KHA 系列产品已获国内相关专 家共识推荐，肝科 DPMA ...

Revenue and Profit Growth - Revenue for the third quarter reached 700,065,714.12 yuan, a year-on-year increase of 47.74%[2] - Net profit attributable to shareholders of the listed company was 239,128,282.41 yuan, up 63.62% compared to the same period last year[2] - Revenue increased by 47.76% to 2,195,690,243.92 yuan, driven by rapid growth in sales of perfusion and adsorption products[7] - Net profit surged by 87.63% to 788,826,841.30 yuan, primarily due to increased sales revenue and a decrease in period expense ratio[8] - Operating revenue for the period reached 2,195,690,243.92 yuan, compared to 1,485,982,086.00 yuan in the same period last year[22] - Net profit attributable to the parent company's owners rose to 2,485,766,350.81 yuan, up from 2,003,918,783.75 yuan at the beginning of the period[21] - Net profit attributable to parent company shareholders reached RMB 791.63 million, a significant increase from RMB 423.66 million in the same period last year[23] - The company's total comprehensive income for the period was RMB 788.83 million, up from RMB 420.44 million in the previous year[24] Asset and Liability Changes - Total assets as of the end of the reporting period were 5,593,125,792.01 yuan, an increase of 0.90% from the end of the previous year[2] - Total assets increased to 5,593,125,792.01 yuan, up from 5,543,301,641.00 yuan at the beginning of the period[21] - Total liabilities decreased to 2,299,898,618.97 yuan, down from 2,390,427,115.63 yuan at the beginning of the period[20] - Total equity attributable to the parent company's owners increased to 3,289,267,081.77 yuan, up from 3,147,475,025.76 yuan at the beginning of the period[21] Cash Flow and Financial Activities - Cash flow from operating activities increased by 47.72% to 871,604,805.56 yuan, driven by higher sales revenue and improved collection[9] - Investment activities resulted in a net cash outflow of 2,177,751,665.93 yuan, mainly due to the purchase of financial products[10] - Financing activities led to a net cash outflow of 727,689,551.18 yuan, primarily due to reduced bank borrowings and increased share repurchase payments[10] - Cash flow from operating activities increased to RMB 871.60 million, up from RMB 590.04 million in the prior year[26] - Investment activities resulted in a net cash outflow of RMB 2.18 billion, primarily due to investment payments of RMB 3.57 billion[26][27] - Financing activities generated a net cash outflow of RMB 727.69 million, with debt repayments totaling RMB 364.16 million[27] Financial Position and Cash Equivalents - The company's monetary funds decreased by 74.35% to 720,879,803.21 yuan, mainly due to the purchase of financial products and payment of share repurchases and dividends[5] - Cash and cash equivalents decreased by 73.71% to 706,919,138.82 yuan, mainly due to the purchase of financial products and share repurchase payments[10] - Cash and cash equivalents stood at 720,879,803.21 yuan, a significant drop from 2,810,294,219.25 yuan at the beginning of the period[18] - The company's cash and cash equivalents at the end of the period stood at RMB 706.92 million, a decrease from RMB 2.69 billion at the beginning of the period[27] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 47,817[11] - Dong Fan holds 44.47% of the shares, totaling 355,131,867 shares[11] - Tang Xianmin holds 2.67% of the shares, totaling 21,336,425 shares[11] - China Bank Co., Ltd. - Huabao CSI Medical ETF holds 2.04% of the shares, totaling 16,261,281 shares[11] - Hong Kong Securities Clearing Company Ltd. holds 1.59% of the shares, totaling 12,689,098 shares[11] - Industrial and Commercial Bank of China Co., Ltd. - E Fund ChiNext ETF holds 1.50% of the shares, totaling 11,998,489 shares[11] - Agricultural Bank of China Co., Ltd. - CSI 500 ETF holds 1.12% of the shares, totaling 8,958,300 shares[11] - Guo Xuerui holds 1.01% of the shares, totaling 8,040,792 shares[11] - Jiang Huanxin holds 1.00% of the shares, totaling 8,000,882 shares[11] - China Bank Co., Ltd. - China Merchants Guozheng Biopharmaceutical Index Fund holds 0.98% of the shares, totaling 7,791,386 shares[11] Expenses and Costs - Operating costs rose by 42.80% to 410,333,473.21 yuan due to increased sales of perfusion and adsorption products[7] - Financial expenses surged by 185.67% to 49,843,991.71 yuan due to a decrease in deposit ratio and increased interest expenses on convertible bonds[7] - Income tax expenses increased by 111.33% to 165,792,667.72 yuan, driven by higher sales revenue and profits[8] - Research and development expenses amounted to 174,715,744.33 yuan, slightly down from 176,357,010.23 yuan in the same period last year[22] - Interest expenses increased to RMB 47.95 million, up from RMB 40.29 million in the previous year[23] Other Financial Metrics - Transactional financial assets increased to 1,993,010,954.97 yuan, primarily due to the purchase of financial products[5] - Accounts receivable financing surged by 1576.55% to 106,616,453.05 yuan, driven by an increase in bank acceptance bills held at the end of the period[5] - Prepayments rose by 143.63% to 28,189,361.94 yuan, mainly due to increased prepayments for raw material purchases[5] - Construction in progress increased by 52.72% to 186,975,903.32 yuan, reflecting higher investments in production equipment and factory construction[5] - Taxes payable surged by 119.17% to 125,821,283.55 yuan, driven by growth in sales revenue and profits[6] - Long-term loans decreased by 31.70% to 276,565,114.40 yuan, partly due to early repayment of some bank loans and reclassification of maturing loans[6] - Government subsidies increased by 49.84% to 52,078,282.13 yuan compared to the same period last year[7] - Trade receivables increased to 92,523,595.64 yuan, up from 74,850,201.41 yuan at the beginning of the period[18] - Inventory decreased to 312,560,202.84 yuan, down from 384,996,423.31 yuan at the beginning of the period[18] - Fixed assets stood at 1,617,425,679.54 yuan, down from 1,633,717,142.19 yuan at the beginning of the period[19] - Basic earnings per share (EPS) for the current period was RMB 0.99, compared to RMB 0.53 in the previous year[24] - Sales revenue from goods and services provided reached RMB 2.31 billion, a rise from RMB 1.78 billion in the previous year[25] - Other income rose to RMB 52.08 million, compared to RMB 34.76 million in the same period last year[23] - The company's third quarter report was not audited[28]

证券代码：300529 证券简称：健帆生物 公告编号：2024-080 债券代码：123117 债券简称：健帆转债 1 1、 健帆转债（债券代码：123117）的转股期限为 2021 年 12 月 29 日至 2027 年 6 月 22 日，最新有效的转股价格为 39.43 元/股。 2、 2024 年第三季度，"健帆转债"未发生转股情况。 3、 截至 2024 年第三季度末，公司剩余可转换公司债券为 9,998,423 张，剩 余票面金额 999,842,300 元人民币。 健帆生物科技集团股份有限公司 关于 2024 年第三季度健帆转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》等有关规定，健帆生物科技集团股份 有限公司（以下简称"公司"）现将 2024 年第三季度可转换公司债券（以下简 称"健帆转债"）转股及公司股本变化情况公告如下： 一、可转换公司债券发行上市情况 （一）可转换公司债券发行情况 经中国证券监督管理 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-079 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2024 年 7 月 16 日 召开了 2024 年第二次临时股东大会，审议通过了《关于注销部分回购股份、减 少注册资本暨修订<公司章程>的议案》，鉴于公司注销回购专用证券账户中的 884.6037 万股股票，使得公司总股本相应减少 884.6037 万股，公司总股本从 80745.1312 万股减少至 79860.5275 万股，公司注册资本由 80745.1312 万元减少 至 79860.5275 万元。 2、核准变更登记通知书。 特此公告。 健帆生物科技集团股份有限公司董事会 8、经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第 三类医疗器械租赁；第二类医疗器械生产；食品销售；第二类增值电信业务；医 疗器械互联网信息服务；药品互联网信息服务；药品批发；药品零售；药品进出 ...

| 证券代码：300529 | 证券简称：健帆生物 公告编号：2024-078 | | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | 健帆生物科技集团股份有限公司 关于奋斗者二号员工持股计划锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 6 月 2 日召开第五届董事会第三次会议、第五届监事会第三次会议，于 2023 年 6 月 19 日召开 2023 年第一次临时股东大会，审议通过了《关于公司<奋斗者二号员 工持股计划（草案）>及其摘要的议案》《关于公司<奋斗者二号员工持股计划管 理办法>的议案》《关于提请公司股东大会授权董事会办理奋斗者二号员工持股 计 划 相 关 事 宜 的 议 案 》 等 议 案 ， 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 鉴于公司奋斗者二号员工持股计划（以下简称"本员工持股计划"或"持股 计划"） 锁定期已于 2024 年 9 月 17 日 ...

证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------|--------------------------|---------------------------| | | \n□ 特定对象调研 | | □ 分析师会议 | 编号： | 2024-005 | | 投资者关系 | □ 媒体采访 √ | | 业绩说明会 | | | | 活动类别 | □ 新闻发布会 | | □ 路演活动 | | | | | □ 现场参观 □ | | 其他（线上会议） | | ...